Health care startups that raised Series B in Asia
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Qingdao Shi | Series B | $30.0M | 2026-11-09 |
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| BionicM | Tokyo | Series B | $4.5M | 2026-11-02 |
| Troovy | Gurgaon | Series B | $10.5M | 2026-10-27 |
| Even Healthcare | Bangalore | Series B | $50.0M | 2026-10-19 |
| Hyperway Pharm | Chengdu | Series B | $14.9M | 2026-10-15 |
| Celaid Therapeutics | Tokyo | Series B | $2.5M | 2026-10-05 |
| HITS | Seoul | Series B | $13.5M | 2026-09-28 |
8 rows of the CSV in 5 of its 18 columns.
- The 1,021 health care startups in Asia whose last round is Series B have raised $21.6B in total.
- 151 of them closed their most recent round in the last 12 months, $2.4B combined.
- The largest of those rounds is D3 Bio's $108.0M Series B, dated December 2025.
- The most recent is Huasaiboman Medical Cell Biology's $30.0M Series B on 9 November 2026.
- TIPS Program is an investor in 15 of them, more than any other fund.
- Biotech is the most common other sector, with 395 companies (39%).
- 13% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 11 to 50 employees (37% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 1,021| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi, China | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai, China | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| BionicM | BionicM develops high-performance robotic prostheses that improve mobility for people with disabilities. | Hardware | Tokyo, Japan | Series B | $4.5M | 2026-11-02 | $15.5M | UTEC - The University of Tokyo Edge Capital Partners, UTokyo Innovation Platform, Shinsei Corporate Investment +1 | 11 to 50 | 2018 |
| Troovy | Troovy makes nutritious foods using natural, wholesome ingredients. | Health care | Gurgaon, India | Series B | $10.5M | 2026-10-27 | $18.5M | Veltis Capital | 11 to 50 | 2021 |
| Even Healthcare | Even is a health-tech company and healthcare provider partnering directly with top hospitals in India. | Fintech | Bangalore, India | Series B | $50.0M | 2026-10-19 | $140.9M | Khosla Ventures, Founders Fund, 8VC +2 | 101 to 250 | 2020 |
| Hyperway Pharm | Hyperway Pharm conducts pharmaceutical research, development, and production. | Health care | Chengdu, China | Series B | $14.9M | 2026-10-15 | $56.8M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, Huaige Capital +1 | 51 to 100 | 2019 |
| Celaid Therapeutics | Celaid Therapeutics develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders. | Biotech | Tokyo, Japan | Series B | $2.5M | 2026-10-05 | $17.1M | UTEC - The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Joyo Capital Partners | 1 to 10 | 2020 |
| HITS | HITS develops artificial intelligence software for drug discovery and pharmaceutical research. | Artificial intelligence | Seoul, South Korea | Series B | $13.5M | 2026-09-28 | $25.1M | Korea Investment Partners, Capstone Partners, Company K Partners +2 | 11 to 50 | 2020 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai, China | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai, China | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou, China | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| MileBot Robotics | MileBot Robotics develops robots for medical and healthcare applications. | Artificial intelligence | Shenzhen, China | Series B | $14.9M | 2026-08-26 | $14.9M | Lenovo Capital and Incubator Group (LCIG), Share Capital, Shangyuan Capital | 101 to 250 | 2016 |
| Butterfly Learnings | Butterfly Learnings provides developmental therapy and inclusive education for children. | Health care | Thane, India | Series B | $6.8M | 2026-08-19 | $12.1M | Venture Catalysts, 100Unicorns, IIMA Ventures +1 | 251 to 500 | 2021 |
| Leadinno Medical Valley | Leadinno Medical Valley produces medical devices that regulate neurological functions. | Health care | Beijing, China | Series B | $29.7M | 2026-08-17 | $90.3M | Fortune Venture Capital, Cowin Capital, Taiyu Investment +2 | 10,001 or more | 2016 |
| Hongxin Biology | Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. | Biotech | Shenzhen, China | Series B | $14.0M | 2026-08-13 | $14.0M | Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group | 11 to 50 | 2021 |
| QuantHealth | QuantHealth develops AI-powered clinical trial simulation software for pharmaceutical and biotechnology organizations. | Artificial intelligence | Tel Aviv, Israel | Series B | $45.0M | 2026-08-04 | $62.0M | Pitango VC, Nina Capital, Accenture Ventures +2 | 101 to 250 | 2020 |
| Layerwave Bio | Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. | Biotech | Daxing, China | Series B | $13.8M | 2026-07-28 | $13.8M | IDG Capital, Addor Capital, Hotung Venture Capital | 51 to 100 | 2020 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai, China | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| Sonosemi Medical | Sonosemi Medical provides medical devices for vascular interventional diagnosis and treatment. | Health care | Shenzhen, China | Series B | $27.3M | 2026-07-08 | $27.3M | Eight Roads Ventures, Co-Stone Venture Capital, Guangzhou Yuexiu Industrial Investment Fund +1 | 101 to 250 | 2020 |
| Emoha Elder Care | Emoha Elder Care delivers integrated healthcare and support services for elderly people in India. | Health care | Haryana, India | Series B | $8.9M | 2026-07-02 | $21.1M | Rainmatter Capital, Gruhas, Lumis Partners | 51 to 100 | 2019 |
| The Indus Valley | The Indus Valley makes cookware designed to help people prepare healthy and delicious meals. | Commerce | Chennai, India | Series B | $17.0M | 2026-06-30 | $21.0M | The Chennai Angels, Lead Invest, DSG Consumer Partners +1 | 11 to 50 | 2016 |
| Dentlink | Dentlink provides digital solutions that help dental clinics and dentists manage their practices. | Health care | Mapo, South Korea | Series B | $7.8M | 2026-06-23 | $11.2M | Springcamp, Translink Investment, Big Basin Capital | 11 to 50 | 2021 |
| Plco | Plco develops a sports platform that helps teams and coaches manage player data and performance analytics. | Health care | Seocho, South Korea | Series B | $2.7M | 2026-06-16 | $9.9M | TIPS Program, Lotte Ventures, Schmidt +1 | 11 to 50 | 2018 |
| Immuneel Therapeutics | Immuneel Therapeutics develops cell and gene therapies to treat cancer. | Health care | Bangalore, India | Series B | $10.5M | 2026-06-08 | $37.6M | Eight Roads Ventures, F-Prime, True North | 51 to 100 | 2018 |
| PROMEDIUS | PROMEDIUS is a healthcare company offering an AI-based medical imaging system for osteoporosis. | Artificial intelligence | Seoul, South Korea | Series B | $14.0M | 2026-06-05 | $24.6M | TIPS Program, CNTTECH, Korea Credit Guarantee Fund +2 | 11 to 50 | 2019 |
| X-MAGTECH | X-MAGTECH provides a technology platform for measuring extremely weak magnetic fields. | Health care | Haidian, China | Series B | $14.8M | 2026-06-04 | $43.5M | IDG Capital, CAS Star, Everest Venture Capital +1 | 101 to 250 | 2018 |
| HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou, China | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| Menovex | Menovex develops and markets laser medical devices for treating oral and skin conditions. | Health care | Shenzhen, China | Series B | $14.8M | 2026-06-02 | $14.8M | Infinity Equity | 2019 | |
| Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai, China | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| Hypershell | Hypershell develops wearable exoskeletons that support walking, hiking, and cycling. | Artificial intelligence | Shenzhen, China | Series B | $50.0M | 2026-05-18 | $121.2M | MiraclePlus, Decent Capital, Vitalbridge Capital | 101 to 250 | 2021 |
Table 1. Health care startups that raised Series B in Asia: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,021.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi, China | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 2 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai, China | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 3 | WIRobotics | WIRobotics develops wearable robots that reduce physical strain and support safe human movement. | Hardware | Yongin, South Korea | Series B | $63.5M | 2026-05-15 | $76.1M | FuturePlay, Hana Ventures, Company K Partners +2 | 11 to 50 | 2021 |
| 4 | Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai, China | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| 5 | MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai, China | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| 6 | Even Healthcare | Even is a health-tech company and healthcare provider partnering directly with top hospitals in India. | Fintech | Bangalore, India | Series B | $50.0M | 2026-10-19 | $140.9M | Khosla Ventures, Founders Fund, 8VC +2 | 101 to 250 | 2020 |
| 7 | Hypershell | Hypershell develops wearable exoskeletons that support walking, hiking, and cycling. | Artificial intelligence | Shenzhen, China | Series B | $50.0M | 2026-05-18 | $121.2M | MiraclePlus, Decent Capital, Vitalbridge Capital | 101 to 250 | 2021 |
| 8 | QuantHealth | QuantHealth develops AI-powered clinical trial simulation software for pharmaceutical and biotechnology organizations. | Artificial intelligence | Tel Aviv, Israel | Series B | $45.0M | 2026-08-04 | $62.0M | Pitango VC, Nina Capital, Accenture Ventures +2 | 101 to 250 | 2020 |
| 9 | CSR Biotech | CSR Biotech provides cell imaging and data processing services for biological research. | Biotech | Haidian, China | Series B | $45.0M | 2026-03-10 | $45.0M | Qiming Venture Partners | 51 to 100 | 2019 |
| 10 | Novamab | Novamab researches and develops new nanobodies. | Biotech | Shanghai, China | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
Table 2. Health care startups that raised Series B in Asia: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | TIPS Program | Startup incubator | Gangneung, South Korea | 15 | 1% | 2 | Plco, PROMEDIUS |
| 2 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 14 | 1% | 3 | Novamab, CSR Biotech, Tingsheng Technology |
| 3 | IDG Capital | Private equity firm | Beijing, China | 11 | 1% | 3 | Layerwave Bio, X-MAGTECH, Yuewei Medical |
| 4 | Matrix Partners China | Venture capital firm | Beijing, China | 9 | 1% | 2 | Alioth, D3 Bio |
| 5 | Legend Capital | Venture capital firm | Beijing, China | 8 | 1% | 1 | Alioth |
| 6 | Korea Investment Partners | Private equity firm | Seoul, South Korea | 6 | 1% | 2 | HITS, LabInCube |
| 7 | Puhua Capital | Venture capital firm | Hangzhou, China | 6 | 1% | 1 | Yuce Biotechnology |
| 8 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 6 | 1% | 1 | HemaCell |
| 9 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 6 | 1% | ||
| 10 | HB Investment | Micro VC fund | Seoul, South Korea | 6 | 1% | ||
| 11 | UTEC - The University of Tokyo Edge Capital Partners | Venture capital firm | Tokyo, Japan | 5 | 0% | 2 | BionicM, Celaid Therapeutics |
| 12 | BioTrack Capital | Venture capital firm | Shanghai, China | 5 | 0% | 2 | Yuce Biotechnology, Rigen Biotech |
| 13 | Lenovo Capital and Incubator Group (LCIG) | Venture capital firm | Beijing, China | 5 | 0% | 1 | MileBot Robotics |
| 14 | Taiyu Investment | Venture capital firm | Beijing, China | 5 | 0% | 3 | Leadinno Medical Valley, Novamab, Tingsheng Technology |
| 15 | Fortune Venture Capital | Venture capital firm | Shenzhen, China | 5 | 0% | 2 | Leadinno Medical Valley, RoboCT |
Table 3. Health care startups that raised Series B in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 395 | 39% | $9.8B |
| Software | 173 | 17% | $2.7B |
| Hardware | 76 | 7% | $818.2M |
| Artificial intelligence | 73 | 7% | $1.6B |
| Commerce | 42 | 4% | $2.1B |
| Fintech | 23 | 2% | $515.3M |
| Education | 17 | 2% | $141.6M |
| Energy | 5 | 0% | $31.5M |
| Cybersecurity | 3 | 0% | $30.0M |
Table 4. Health care startups that raised Series B in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 1,021 | 100% | $13.9M |
Table 5. Health care startups that raised Series B in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| China | 664 | 65% |
| South Korea | 136 | 13% |
| Japan | 59 | 6% |
| India | 58 | 6% |
| Israel | 51 | 5% |
| Singapore | 18 | 2% |
| Taiwan | 10 | 1% |
| Hong Kong | 9 | 1% |
| United Arab Emirates | 5 | 0% |
| Indonesia | 4 | 0% |
| Thailand | 1 | 0% |
| Malaysia | 1 | 0% |
Table 6. Health care startups that raised Series B in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Health care startups that raised Series B in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 8 | 5% | $98.3M |
| October 2026 | 10 | 7% | $251.1M |
| September 2026 | 12 | 8% | $352.9M |
| August 2026 | 11 | 7% | $138.6M |
| July 2026 | 8 | 5% | $216.1M |
| June 2026 | 16 | 11% | $173.1M |
| May 2026 | 9 | 6% | $255.3M |
| April 2026 | 9 | 6% | $97.6M |
| March 2026 | 17 | 11% | $227.4M |
| February 2026 | 14 | 9% | $136.4M |
| January 2026 | 16 | 11% | $176.6M |
| December 2025 | 13 | 9% | $230.5M |
| November 2025 | 8 | 5% | $52.7M |
Table 8. Health care startups that raised Series B in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 130 | 13% | $2.1B |
| 2025 | 117 | 11% | $1.7B |
| 2024 | 96 | 9% | $1.2B |
| 2023 | 104 | 10% | $1.4B |
| 2022 | 124 | 12% | $3.2B |
| 2021 | 100 | 10% | $3.2B |
Table 9. Health care startups that raised Series B in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 6 | 1% |
| 2020 to 2022 | 126 | 12% |
| 2015 to 2019 | 485 | 48% |
| 2010 to 2014 | 236 | 23% |
| Before 2010 | 161 | 16% |
Table 10. Health care startups that raised Series B in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 108 | 12% |
| 11 to 50 | 349 | 37% |
| 51 to 100 | 187 | 20% |
| 101 to 250 | 151 | 16% |
| 251 to 500 | 74 | 8% |
| 501 to 1,000 | 29 | 3% |
| 1,001 to 5,000 | 25 | 3% |
| 5,001 to 10,000 | 4 | 0% |
| 10,001 or more | 5 | 1% |
Table 11. Health care startups that raised Series B in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its most recent funding round is Series B and its headquarters is in Asia. On 16 November 2026 that is 1,021 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 1,021 rows: 244 have no round amount, 0 no city and 283 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Asia whose last round is Series B are on the list?
- 1,021, in the file dated 16 November 2026. 151 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 1,021 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.